Introduction
In addition to the cyclin-dependent kinase inhibitor p16 INK4a , the INK4a locus encodes a second gene product p14 ARF (p19 ARF in mouse), which is transcribed in an Alternative Reading Frame from an additional exon 1b (Mao et al., 1995; Quelle et al., 1995) . p14 ARF has been identi®ed as a potent tumor suppressor in vitro and in vivo, respectively (Kamijo et al., 1997; Serrano et al., 1996; Sherr, 2000) . Expression of p14 ARF can be induced upon activation of various cellular and viral oncogenes including c-myc , E2F, E1A (de Stanchina et al., 1998) , Ras v-Abl (Radfar et al., 1998) , or cellular stress such as serum starvation (Inoue et al., 1999) . In turn, up-regulation of p14 ARF mediates accumulation of p53 via sequestration of the p53-antagonist Mdm-2 (Hdm-2 in humans) through the ubiquitin/proteasome pathway. Thus, p14 ARF relieves the Mdm-2-mediated degradation of p53 and thereby prolongs the p53 protein half life (Pomerantz et al., 1998) . This allows stabilization of p53 and the subsequent activation of p53 downstream eectors such as p21 and Bax. P14 ARF has been shown to protect from uncontrolled growth and tumorigenesis induced by hyperproliferative stimuli (Sherr, 2000) . In turn, functional inactivation of p14 ARF accelerates tumorigenesis and promotes chemoresistance by disabling p53 (Eischen et al., 1999; Schmitt et al., 1999) . It had been suggested earlier that p14 ARF and p53 act in overlapping pathways rather than strictly sequentially (Carnero et al., 2000) . In addition to the p53-dependent eects, the murine homologue, p19 ARF , was shown to exert cell cycle arrest independently from p53 and Mdm-2, Rb , p21
CIP/WAF and p27 KIP1 (Groth et al., 2000) . Only recently have some of the molecular targets mediating p53-independent eects of p14 ARF been identi®ed, such as E2F-1 (Eymin et al., 2001; Martelli et al., 2001) , HIF-1a (Fatyol and Szalay, 2001) , topoisomerase I , and spinophilin/neurabin II, a regulatory subunit of the protein phosphatase 1 catalytic subunit (Vivo et al., 2001 ). Many aspects of p14 ARF signaling remain unclear, however, this holds true especially for the mechanisms of p14 ARF -mediated induction and execution of cell death.
Programmed cell death (apoptosis) plays a central role in tissue homeostasis during both development and adult life. The majority of cancer therapies activates the mitochondrial pathway of apoptosis which is tightly controlled by proteins of the Bcl-2 family (Adams and Cory, 1998) . While Bcl-2, Bcl-x L and other apoptosis preventing members of the family inhibit the activation of mitochondria, the pro-apoptotic Bcl-2 homologs Bax, Bak and Bok/Mtd promote release of cytochrome c and initiate the mitochondrial permeability shift transition, i.e. the breakdown of the mitochondrial membrane potential (Hengartner, 2000) . This leads to the formation of the mitochondrial apoptosome by APAF-1, cytochrome c and procaspase-9 resulting in processing of the procaspase-9 to the active holoenzyme (Li et al., 1997) . Active caspase-9 in turn activates the network of executioner caspases and initiates thereby the cleavage of multiple structural and regulatory proteins .
Previously, we have shown that the loss or dysregulation of apoptosis promoting genes such as p53 or Bax is associated with a poor prognosis in a variety of cancer types (Hermann et al., 2001; Prokop et al., 2000; Sturm et al., 2001 ) and the development of drug resistance (Bosanquet et al., 2002) . The reconstitution of individual components of the p53/Bax/ caspase-3 apoptosis signaling cascade in various carcinoma and lymphoma cell lines could restore sensitivity to pro-apoptotic stimuli and overcome resistance to drug-induced apoptosis in tumor cells displaying acquired resistance to chemotherapy in vitro Friedrich et al., 2001) .
In the present work, we aimed to investigate the eects of p14 ARF overexpression in carcinoma cells with defects in p53 and Bax, often associated with resistance to cytotoxic anticancer therapies. To this end, we constructed a replication-de®cient adenoviral expression vector for p14 ARF . Adenovirus-mediated overexpression of p14 ARF resulted in massive apoptosis as evidenced by breakdown of the mitochondrial membrane potential, caspase activation and fragmentation of genomic DNA in a several tumor cell lines irrespective of the presence or absence of functional cellular p53. Interestingly and in contrast to our expectations, strong induction of apoptosis was also seen in the p53/Bax-mutated prostate carcinoma cell line DU145 which is completely void of Bax and highly resistant to a variety of anticancer drugs and death receptor-triggered apoptosis. Although reconstitution of Bax expression in DU145 cells strongly increased sensitivity for drug-induced apoptosis, the sensitivity for p14 ARF -triggered apoptosis was not further enhanced. In the same line, p14 ARF eciently triggered apoptosis in HCT116 colon carcinoma cells lacking p53 (HCT116 p53 7/7 ) or Bax (HCT116 Bax
7/7
). In contrast, overexpression of antiapoptotic Bcl-x L abrogated p14 ARF -triggered induction of apoptosis. Our data therefore indicate that overexpression of p14 ARF may trigger eciently apoptotic cell death through the mitochondrial pathway which occurs independently from the p53/Bax pathway of apoptosis. In addition, we suggest that p14 ARF targets an activator of the mitochondrial death pathway which can be inhibited by Bcl-x L but is either independent from or acts downstream of Bax.
Results
Generation of the adenoviral vector Ad-p14 ARF Previous studies have shown that p14 ARF acts through engagement of the p53 tumor suppressor pathway. This suggested the participation of downstream eectors of p53 in mediating the cell cycle and apoptosis eects in consequence of p14 ARF induction by a variety of stimuli. While a wealth of information is available on the upstream requirements for p14 ARFtriggered apoptosis (Sherr, 2000) only very limited information is available on the cell death pathways mediating apoptosis induced by p14 ARF . To further investigate the mechanisms of apoptosis induction via p14 ARF and to test whether it is possible to overcome apoptosis resistance in carcinoma cells by targeting this upstream regulator of the p53/Bax pathway, we designed a replication-de®cient adenoviral vector based on adenovirus serotype 5 to allow overexpression of the transgene. P14 ARF was cloned under control of a CMV-promoter and the expression cassette was inserted into the adenoviral region E1 thereby replacing it. In addition, the adenoviral E3 region was deleted by homologous recombination (Figure 1a ). Correct sequence of the p14 ARF expression cassette was con®rmed by DNA-sequencing of adenoviral stocks (data not shown). Recombination with E1 supplied intrans by the HEK293 producer cells resulting in replication-competent wild-type adenovirus was ruled out by polymerase-chain-reaction (PCR) as well as a plaque assay in A549 lung cancer cells (Anderson et al., 2000) . Transduction eciency at MOIs of 25 and 50 was above 95% in all cell lines tested (including U-2OS, SAOS-2, DU145, HCT116, and D283) as con®rmed by infection with an Ad-lacZ control virus allowing conditional expression of the lacZ reporter gene (data not shown).
Expression of functional p14 ARF protein was veri®ed by infection of the p53 wild-type U-2OS osteosarcoma cell line with p14 ARF adenovirus (Ad-p14 ARF ). As shown in Figure 1b , transduction of U-2OS cells at a MOI of 25 resulted in overexpression of p14 ARF 48 h post infection. As expected, an up-regulation in the expression of both p53 and p21 could be detected by immunoblotting, whereas no changes were observed in the expression levels of Bax and cdk-4, the latter serving as a protein loading control.
Induction of apoptosis by p14
ARF is independent from p53 and Bax
Adenoviral transduction of U-2OS cells with Adp14
ARF strongly induced apoptotic cell death ( Figure 2a ). Western blot analysis showed that this was associated with induction of p53 protein, as could be expected from the literature.
To investigate the requirement of functional p53 for induction of apoptosis by the p14 ARF vector, we studied the pro-apoptotic eects upon adenovirusmediated overexpression of p14 ARF in both p53-pro®cient and p53-de®cient cell lines. The osteosarcoma cell lines U-2OS (p53 wild-type) and SAOS-2, latter of which is negative for p53 due to a biallelic deletion of the p53 gene, as well as the p53-mutated DU145 prostate cancer cell line were infected with Ad-p14 ARF at a MOI of 25. The induction of apoptosis was measured by¯ow cytometry to determine the extent of genomic DNA fragmentation, i.e. the occurrence of a characteristic nuclear hypodiploid DNA content. A substantial increase in the number of apoptotic U-2OS cells was observed as early as 48 h post transduction with Ad-p14 ARF (data not shown) with a maximum peak at 72 h. In contrast, only minor apoptosis was observed in mock-treated and control vector-transduced cells (Figure 2a, upper panel) . Interestingly, overexpression of p14 ARF strongly increased the number of apoptotic cells in both the p53-deleted SAOS-2 (after 72 h) and the p53-mutated DU145 cells (96 h post transduction), respectively (Figure 2a, middle and lower panel) . For all three cell lines, this eect was dose-dependent starting to increase at a MOI as low as 1 and reaching a maximum at MOIs of up to 25 ( Figure 2b ). As depicted in Figure 2c , transgene expression could be detected 48 h after infection and increased in a dose-dependent manner in all three cell lines examined. In particular, high levels of expression were seen in U-2OS and SAOS-2, respectively, even at low MOIs. These data strongly suggest that overexpression of p14 ARF through adenovirus is capable of inducing apoptosis irrespective of the presence or absence of functional cellular p53.
Induction of apoptosis by p14
ARF in Bax reconstituted DU145 cells
In addition to the mutation of p53, the DU145 cells are devoid of Bax due to a frameshift mutation in the G8 tract of the Bax gene (data not shown). The resulting G9 tract in the Bax gene introduces a premature stop codon which results in loss of protein expression as demonstrated previously for LoVo cells . Nevertheless, no marked dierence was apparent in their ability to undergo apoptosis upon p14 ARF overexpression as compared with p53-deleted but Baxpositive SAOS-2 cells. This suggested that the ability of p14 ARF to induce apoptosis is independent from Bax. To gain additional support for this hypothesis, we reconstituted Bax expression by stable expression in Bax-negative DU145 cells. To this end, a retroviral vector, HyTK ± Bax (Weinmann et al., 1997) , containing the wild-type Bax-a cDNA was used to stably transduce DU145 cells. Of several individual clones selected and screened for transgene expression by immunoblotting (data not shown), one representative clone displaying moderate Bax expression (DU145 ± Bax) was chosen and investigated in parallel with a HyTK control vector-transduced clone (DU145-mock).
Both DU145-mock and DU145-Bax cells were infected with Ad-p14 ARF at a MOI of 25 and apoptotic cells were detected by¯ow cytometry 24 ± 96 h post infection. As expected from the experiments in the Baxnegative DU145 cells showing strong induction of apoptosis upon overexpression of p14 ARF , the susceptibility to undergo apoptosis did not dier between DU145 and DU145-mock cells. Furthermore, we did not observe an increased rate of apoptosis in DU145 cells reconstituted with Bax in comparison to DU145-mock cells as determined 96 h after infection ( Figure  3a) . Similar to the previous experiments, this eect was dose-dependent and could be observed within the same range of MOI (Figure 3b, left panel) .
In contrast, DU145 cells reconstituted for Bax expression were clearly more susceptible to druginduced apoptosis upon exposure to the anthracyclin epirubicin and other DNA damaging compounds (data Time course experiments revealed a substantial increase in apoptosis at 96 h post infection ( Figure  3c ). Western blot analysis for protein expression showed a marked overexpression of p14 ARF , but neither the expression of the mutated p53 nor that of p21 was induced in the DU145-mock or DU145 ± Bax cells. Regarding Bax, the DU145 ± Bax cells showed the constitutive expression of the Bax transgene. As expected in view of the Bax mutation in the DU145 cells, we did not detect an induction of Bax protein in the DU145 mock cells while the DU145 ± Bax cells expressed the retrovirally reconstituted Bax-a ( Figure  3d ). Taken together, these results indicate that adenovirus-mediated overexpression of p14 ARF induces programmed cell death in cancer cells highly resistant to drug-induced apoptosis and irrespective of a functional p53/Bax pathway.
P14
ARF mediates cell death by the mitochondrial pathway of apoptosis Although the ability of p14 ARF to induce apoptosis appears to be independent of functional Bax, we asked whether adenovirus-mediated overexpression of p14 ARF activates the mitochondrial pathway of apoptosis. Hence, we analysed the mitochondrial permeability shift transition (DCm) as an indicator for breakdown of the mitochondrial membrane potential during apoptosis induction. To this end, cells were harvested 72 h (U-2OS and SAOS-2) or 96 h (DU145-mock/-Bax) after infection with Ad-p14 ARF , and incubated with JC-1, a cationic dye that exhibits mitochondrial membrane potential-dependent¯uorescence. The presence of an intact mitochondrial potential in live cells or the disruption of the mitochondrial membrane ARFtransduction and gene expression showed that all cell lines examined underwent a disruption of the mitochondrial membrane potential irrespective of functional p53. (Figure 4a ). This was most prominent in cell lines expressing wild-type Bax (U-2OS, SAOS-2).
In addition, both Bax mutated DU145-mock and Baxreconstituted DU145-Bax showed a signi®cant DCm upon Ad-p14 ARF transduction. These data indicate that the induction of p14 ARF triggers a Bax-independent DCm and activation of the mitochondrial apoptosis signaling cascade.
To test whether the disruption of the mitochondrial membrane potential was accompanied by activation of the caspase cascade, we performed¯ow cytometric ARF triggers p53/Bax-independent apoptosis PG Hemmati et al detection of caspase activation 24 ± 96 h after transduction with Ad-p14 ARF . Cells were harvested and incubated with the cell-membrane permeable, FITClabelled conjugate of the pan-caspase inhibitor VAD ± FMK which allows delivery of the inhibitor into the cell where it binds to active caspases thereby serving as an in situ marker for caspase activation and apoptosis. As shown in Figure 4b , caspase activation started 72 h after Ad-p14 ARF transduction and increased in a dosedependent manner (data not shown). Taken together, these results suggest that adenovirus-mediated overexpression of p14 ARF can activate the mitochondrial pathway of apoptosis as indicated by breakdown of the mitochondrial membrane potential subsequently followed by caspase activation irrespective of the presence of Bax.
To further verify that p14 ARF is capable of inducing mitochondrial apoptosis independently from the presence of either p53 or Bax, we determined induction of mitochondrial permeability shift transition and subsequent activation of caspases in HCT116 colon cancer cells lacking functional p53 (HCT116 ± p53 7/7 ) (Bunz et al., 1998) or Bax (HCT116 ± Bax 7/7 ) as a consequence of homozygous deletion. In contrast to Bax-reconstituted DU145 cells, the possibility of additional defects in the apoptotic signaling cascade due to selection pressure in consequence of Bax-reconstitution can be largely excluded in HCT116 ± Bax 7/7 . As shown in Figure 5a , adenovirus-mediated overexpression of p14 ARF induced a breakdown of the mitochondrial membrane potential irrespective of the presence or absence of functional cellular p53 or Bax. This eect was dose-dependent, starting to increase at an MOI of 10 and reached a maximum at an MOI of 50 at 72 h after infection (data not shown). As expected from the previous experiments in DU145 cells, there was no major dierence in permeability shift transition between cells expressing wild-type p53 or Bax as compared with those homozygously deleted for either gene. In analogy, activation of caspases was observed in both knock-out cells, HCT116 ± p53
and HCT116 ± Bax 7/7 , to a similar extent when compared to wild-type cells (Figure 5b ). Taken together, these data demonstrate, that the mitochondrial apoptosis cascade can be activated by p14 ARF irrespective of both p53 and Bax. Similarly, p14 ARF triggered cell death as measured by DNA fragmentation in the HCT116 cells and the isogeneic p53 and Bax knock-out cells (Figure 5c ). Noteworthy, p14 ARFinduced DNA fragmentation was lower in the HCT116 ± p53 7/7 cells as compared with the HCT116 control cells. This, however, is not due to decreased cell death but re¯ects a lower rate of DNA fragmentation in the HCT116 ± p53 7/7 cells. Overall cell death as determined by Trypan blue exclusion (data not shown) was above 90% in both HCT116 ± p53 7/7 and the HCT116 p53 wild-type control cells, being in line with the results obtained by measurement of mitochondrial permeability shift transition and pancaspase activities.
ARF -induced mitochondrial apoptosis is inhibited by Bcl-xL
In view of the Bax-independent activation of mitochondrial apoptosis, we asked whether p14 ARF -mediated activation of mitochondrial apoptosis can be counteracted by anti-apoptotic members of the Bcl-2 family. To this end, D283 glioblastoma cells stably overexpressing Bcl-x L or mock-transfected cells were infected with increasing MOIs of Ad-p14 ARF and . Trypan blue dye exclusion demonstrated induction of cell death in 490% in both the p53 de®cient and p53 pro®cient HCT116 cells (data not shown) assayed for activation of caspases and apoptotic DNAfragmentation. As shown in Figure 6a , activation of caspases in D283 mock cells could be induced as early as 48 h after infection with Ad-p14 ARF , reaching a maximum after 96 h. This eect was dose-dependent starting at an MOI of 10, steadily increasing to an MOI of 50 (Figure 6b ). In contrast, Bcl-x L transfected D283 cells were protected from p14 ARF -induced caspase activation (Figure 6a and b) . Similarly, induction of DNA-fragmentation by p14
ARF was clearly diminished in D283 cells overexpressing Bcl-x L , whereas D283 mock cells were sensitive (Figure 6c ). Taken together, p14 ARF -induced mitochondrial apoptosis, although clearly independent from either p53 or Bax, can be inhibited by overexpression of anti-apoptotic Bcl-2 homologs such as Bcl-x L .
Discussion
The propensity of oncogenes to trigger the p53-pathway of apoptosis was recently shown to be mediated through the second gene product of the INK4a gene locus, p14 ARF (Sherr, 2000) . The ®rst gene product discovered to be transcribed from the INK4a locus, the cyclin-dependent kinase inhibitor p16 INK4a , is known to be induced by DNA-damage via p53-independent mechanisms, and mediates an arrest at the G1 restriction point of the cell cycle . In contrast, p14 ARF , the second gene product of the INK4a locus, activates the p53 pathways for cell cycle arrest and apoptosis. The activation of the p53 pathways by p14 ARF was shown to be mediated through sequestration of Mdm-2, an antagonist of p53, via the proteasome. This in turn stabilizes the p53 protein and subsequently activates p53-dependent events of cell cycle arrest and apoptosis (Pomerantz et al., 1998; Stott et al., 1998) . The cell cycle inhibitory function of p14 ARF was suggested to depend on p53, presumably by induction of p21 CIP/WAF . Recently, however, a p53- and p21-independent (Groth et al., 2000) cell cycle inhibitory eect of p14 ARF was described. Both p14 ARF and p16
INK4a are regulated by independent promoters (Sherr, 2000) and have been shown to be inactivated independently from each other by promoter methylation or concomitantly by chromosomal 9p deletions in various cancer types (Burri et al., 2001; Iida et al., 2000; Kumar et al., 1998; Nakamura et al., 2001) . The generation of knock-out mice for p16 INK4a or p14 ARF has clearly demonstrated that both genes are involved in tumor suppression (Kamijo et al., 1999; Krimpenfort et al., 2001 ). In addition, recent evidence suggests that loss of p14 ARF not only mediates resistance to apoptosis in consequence of cell cycle dysregulation (Sherr, 2000) but is also involved in tumor progression and the development of drug-resistance (Schmitt et al., 1999) .
Therefore, and in continuation of our earlier work, we were interested to study p14 ARF overexpression as a potential strategy to overcome resistance to cytotoxic therapy in cancer. In the present work, we show that adenoviral overexpression of p14 ARF induces apoptosis in a panel of tumor cell lines by itself. Interestingly, the induction of apoptosis occurred independently of the genetic p53 status, since both SAOS-2 osteosarcoma cells (biallelic p53 deletion) and DU145 prostate carcinoma cells (mutated p53) underwent apoptosis to a similar extent as the p53 wild-type U-2OS cells. The capacity of p14 ARF to interfere with apoptosis or cell cycle control had been previously ascribed solely to the presence of a functional p53/Mdm-2 pathway Pomerantz et al., 1998; Stott et al., 1998) . In the same line, a recent report using adenovirus- ARF (50 MOI) at various time points as indicated. Standard deviation was less than 5% in all cases examined. Black bars: D283-mock, white bars: D283-Bcl-x L . Cells were seeded in triplicates and one representative of three independent experiments is shown. Standard deviation was below 5% in all cases examined p14 ARF triggers p53/Bax-independent apoptosis PG Hemmati et al mediated overexpression of p14 ARF in mesothelioma cells showed induction of apoptosis in cells with wildtype p53. This report also provided preliminary evidence that p53 knock-out cells are at least partially defective to undergo apoptosis upon overexpression of p14 ARF (Yang et al., 2000) . In contrast, we show that HCT116 cells with a homozygous p53 deletion are as sensitive to p14 ARF -induced apoptosis as the isogeneic p53 wild-type HCT116 cells. The isolated observation of DNA fragmentation suggests a lower but signi®cant sensitivity for p14 ARF -induced apoptosis in the p53 knock-out cells. Nevertheless, the measurement of caspase-activities, mitochondrial permeability shift transition and overall cell death by Trypan blue exclusion clearly show similar sensitivities in p53 pro®cient versus p53 knock-out HCT116 cells, thereby suggesting a disturbed DNA fragmentation upon p14 ARF exposure in the HCT116-p53 7/7 cells. Although it was proposed earlier that p14 ARF may activate p53-independent (apoptotic) pathways, in particular when combined with additional death signals (de Stanchina et al., 1998; Zindy et al., 1998) , induction of massive apoptosis through overexpression of p14 ARF in cells lacking functional p53 has not been reported previously.
Several p53-independent targets of p14 ARF have been described recently which could be implicated in cell cycle control (Eymin et al., 2001; Martelli et al., 2001) , cell growth (Vivo et al., 2001) , DNA-replication/ damage-repair , or adaptation to hypoxic stress (Fatyol and Szalay, 2001 ). These could also be involved in so far unknown proapoptotic signaling pathways activated by p14 ARF . Consistent with this possibility, our data clearly demonstrate that p14 ARF utilizes p53 and Baxindependent pathways for induction of cell death. Although we did not address the question which alternative pathways are utilized by p14 ARF for death signaling in the present study, work is currently under way to elucidate the underlying mechanisms that allow induction of apoptosis by p14 ARF under circumvention of the p53/Mdm-2/Bax pathway. This is of special interest in view of our ®ndings regarding the independence of p14 ARF -induced apoptosis from the apoptosis promoting Bcl-2 homolog Bax. Members of the Bcl-2 family are key regulators of apoptosis (Adams and Cory, 1998; Hengartner, 2000) . Deregulated overexpression of Bcl-2 is one of the key events in the development of lymphomas carrying the t(14;18) translocation and may contribute to resistance to therapy. Similar data have been obtained for Bcl-x L and other apoptosis-preventing homologs (Adams and Cory, 1998) . The ability of Bcl-2, Bcl-x L and their homologs to prevent apoptosis is antagonized by the pro-apoptotic members of the Bcl-2 family, such as Bax, which may directly activate mitochondria resulting in the release of cytochrome c (Jurgensmeier et al., 1998) and the induction of the mitochondrial permeability transition.
In previous studies, we demonstrated that cancer cells frequently display a defect in Bax expression (Bosanquet et al., 2002; Prokop et al., 2000; . Reconstitution of Bax restored apoptosis sensitivity for serum starvation, Fas-triggered death or exposure to DNA damaging agents such as anthracyclins in vitro (Bargou et al., 1995; Wagener et al., 1996) . Interestingly, p14
ARF induced programmed cell death in DU145 cells which do not express Bax, a central activator of mitochondrial apoptosis. While overexpression of Bax in DU145 cells restored the sensitivity to drug-induced apoptosis, the already high sensitivity to p14 ARF -induced cell death could not be further increased. Interestingly, we observed that, disregardless of Bax expression, adenoviral overexpression of p14 ARF triggered mitochondrial permeability shift transition and the activation of the caspase cascade in both Bax pro®cient and de®cient cells. This indicates that p14 ARF is capable of circumventing the loss of Bax (and/or additional death promoting molecules) which is a frequent event in cancer and, nevertheless, is capable of triggering the mitochondrial pathway of programmed cell death and execution of apoptosis via the caspase cascade.
Recently, a number of apoptosis pathways were described that interconnect distinct signaling cascades (Daniel, 2000) . Death receptor-triggered recruitment of adapter molecules, such as FADD, leads to activation of procaspase-8, which may then trigger the mitochondrial apoptosis machinery via the cleavage of Bid to tBid, resulting in cytochrome c release and permeability shift transition Li et al., 1998) . Thus, caspase-8 links, via Bid cleavage, the death receptor to the mitochodnrial pathway of apoptosis. Therefore, one possibility for the propensity of p14 ARF to induce Bax-independent apoptosis could be the activation of a program which triggers the cytoplasmic death receptor machinery and leads to activation of caspases, resulting in the induction of mitochondrial permeability shift transition. The relevance of such an activation of the death receptor signaling machinery by nuclear signals, e.g., during DNA damage, has been a matter of controversial debate in the recent past . Nevertheless, such a mechanism would be in-line with our observation of caspase activation preceding mitochondrial permeability shift transition in the DU145 cells.
Another possibility to explain independence from Bax in p14 ARF -induced apoptosis could be the recruitment of Bax homologues such as Bak and Bok during apoptosis induction. The Bax homologue Bok appears to be expressed, however, in a tissue restricted manner (Hsu et al., 1997) , and there is so far no published evidence for Bok expression in osteosarcoma, glioblastoma and colorectal or prostate carcinoma cells. In addition, the expression of Bak as measured by Western blot analysis is rather weak in the tumor cell lines investigated (data not shown), which is in line with a loss of Bak during carcinogenesis (Krajewska et al., 1996) . Especially in the DU145 cells, a panel of various stimuli, including death receptor signaling and cytotoxic drugs, did not induce apoptosis disregardless of the low expression of Bak (data not shown). Overexpression of Bak, however, can restore sensitivity of drug-resistant breast cancer cells to epirubicininduced apoptosis (Radetzki et al., 2002) . This, together with the fact that Bax-negative DU145 cells are refractory to epirubicin-induced cell death, while Bax-reconstituted cells are sensitive, indirectly suggests that Bak is not expressed in functionally relevant levels in the DU145 cells. Experiments are, however, under way to determine whether apoptosis induction through p14 ARF depends on the expression levels of Bak or other apoptosis promoting members of the Bcl-2 gene family such as Bik/Nbk.
Apart from the independence from Bax, we therefore addressed the question whether p14
ARF -induced apoptosis can be blocked by apoptosis preventing members of the Bcl-2 family. Experiments performed in D283 glioblastoma cells overexpressing Bcl-x L show that p14 ARF activates mitochondrial apoptosis via a Bcl-x L sensitive pathway. In view of this discrepancy between independence of p14 ARF -induced apoptosis from Bax and protection by Bcl-x L , our data strongly suggest that p14 ARF utilizes novel pathways for induction of cell death and further underline the notion that its apoptotic capacity may be mediated by targeting genes independently from the p53/Mdm-2 rheostat and the downstream eector Bax. In this line, we favor a model where p14
ARF triggers an activator of mitochondrial apoptosis which acts either independently or downstream of Bax but which is under control of apoptosis preventing Bcl-2 homologs, such as Bcl-x L (Figure 7 ). This model is also supported by previous reports on the direct activity of Bax on mitochondria (Jurgensmeier et al., 1998) and the independence of Bax and Bcl-x L from each other in the regulation of apoptotic cell death (Simonian et al., 1996) , which suggests a common target mediating the proapoptotic eect of Bax and which can be inhibited by Bcl-2/Bcl-x L . This model could explain a range of discrepancies created by the still generally accepted model of an antagonistic Bax/ Bcl-x L interaction, e.g. via di-or multimerization. One of these possible targets is the VDAC/ANT/Cyclophylin D complex, which may also recruit additional proteins such as the peripheral benzodiazepine receptor (Crompton, 2000; Tsujimoto and Shimizu, 2000) . The elucidation of p14 ARF -induced activation of the mitochondrial apoptosis pathway may therefore also help to further elucidate the still enigmatic mode of function of apoptosis promoting and preventing Bcl-2 homologs.
Furthermore, the inactivation of p14 ARF , p53 and Bax, i.e. the disturbance of cellular death programmes, is a critical step in tumorigenesis. The inactivation of such key regulators of cell death concomitant with deregulation of oncogenes such as K-ras, the E2Fs or c-myc may induce malignant transformation, while it is well accepted that deregulated activation of the oncogenes alone induces cell death (Evan and Vousden, 2001) . In this line, our data may indicate that the restoration of p14 ARF by overexpression in tumor cells (i.e. in the context of deregulated oncogenes) may be critical to trigger tumor suppressor programmes leading to cell death, irrespective of the loss of Bax or p53. This of special interest in view of the frequent inactivation of the p14 ARF /p53/Bax pathway in cancer.
Therefore, the fact that p14 ARF induced apoptosis disregardless of loss of two key regulators of cell death indicates that the triggering of p14 ARF and the consecutive signaling events of Bax-independent mitochondrial activation and cell death could represent a useful target for the development of novel cancer therapies, either by the viral transfer of p14 ARF itself or by the use of small molecules targeting the critical Figure 7 Schematic model for the induction of mitochondrial apoptosis by p14 ARF . While DNA damage, e.g. by anticancer drugs, activates the mitochondrial apoptosis machinery via p53 and Bax, p14 ARF bypasses both p53 and Bax to trigger the mitochondrial pathway. Data from the literature and this report point out that Bax and Bcl-x L independently from each other regulate a downstream eector (such as VDAC) which mediates mitochondrial activation. p14 ARF could target this key switch by circumventing Bax. This model would still retain the possibility of inhibition of this key switch by Bcl-x L . Mitochondrial activation leads to activation of the caspase cascade and demise of the cell by apoptosis structures for the activation of p14 ARF -mediated apoptosis.
Materials and methods

Cell culture
HEK293, U-2OS, SAOS-2, DU145, and A549 were obtained from the ATCC (Manassas, USA), or the DSMZ (Braunschweig, Germany). HCT116 ± p53 7/7 and HCT116 ± Bax 7/7 knock-out cells as well as the corresponding isogeneic control cells HCT116 ± p53 +/+ and HCT116 ± Bax +/+ were provided by Dr Bert Vogelstein, Johns Hopkins Cancer Center, Baltimore, USA (Bunz et al., 1998; Zhang et al., 2000) . Cells were grown in DMEM/high glucose (4.5 g/l) medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 0.1 mg/ml streptomycin (all from GIBCO, Karlsruhe, Germany) at 378C with 5% CO 2 in fully humidi®ed atmosphere. D283 glioblastoma cells stably overexpressing Bcl-x L by retrovirus-mediated gene-transfer (Poppe et al., 2001) were grown in RPMI1640 medium supplemented with 10% FCS, 100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were infected with recombinant, replication-de®cient adenovirus diluted in cell culture medium in the absence of FCS or antibiotics at the indicated multiplicity of infection (MOI) for 2 h at 378C or were mock treated with serum free medium only. Thereafter, equal amounts of medium supplemented with 20% FCS, 200 U/ml penicillin and 0.2 mg/ml streptomycin were added.
Construction of recombinant adenoviral vectors
The method for production of recombinant, replicationde®cient adenoviral vectors was a modi®cation of the procedure described earlier (Chartier et al., 1996) and adenoviral plasmids were kindly provided by HepaVec AG (Berlin, Germany; www.hepavec.com). For the construction of Ad5 ± CMVp14 ARF (Ad-p14 ARF ) cDNA was excised from pBlueIIks-p14 ARF (generously provided by Dr KG Wiman and Dr U Klangby, Cancer Center Karolinska, Stockholm, Sweden) as a BamHI/XhoI fragment and cloned into pcDNA3 (Invitrogen, Karslruhe, Germany). The resulting CMV-promoter driven p14 ARF expression cassette was then cloned into the shuttle vector pHVAd2 as a BglII/PvuII fragment (pHVAd2-CMVp14 ARF ). Finally, a PacI/NotI fragment of pHVAd2 ± CMVp14 ARF was inserted into the Ad5 genomic DNA by homologous recombination with the pHVAd1DE3 (containing the complete adenovirus 5 genome deleted in E3) in the E. coli strain BJ5183 RecBC ± sbcB thereby replacing the E1 region. For the large-scale production of recombinant adenovirus, 5 mg of each adenoviral construct were transfected into HEK293 cells using calcium phosphate/DNA precipitates and adenoviral plaques were propagated according to standard procedures as described (Chartier et al., 1996) .
Stable expression of Bax by retroviral infection of DU145 cells
For stable expression of Bax in the Bax-negative DU145 cells, the retroviral vector HyTK ± Bax (Weinmann et al., 1997) which contains the human Bax-a cDNA under the control of a CMV promoter was chosen. Supernatant of the virus producing packing cell line FLYRD-19 (Cosset et al., 1995) was used to infect DU145 cells in the presence of 8 mg/ml polybrene (Sigma, GruÈ nwald, Germany). Hygromycin (0.5 mg/ml) was added 48 h later and following 3 weeks of selection, stable transfectants were subcloned. Bax expression of several individual clones was determined by Western blot analysis.
Antibodies and reagents
Mouse monoclonal anti-p14 ARF antibody (clone 14P02, raised against full-length recombinant human p14 ARF protein) was purchased from NeoMarkers (Fremont, CA, USA) and mouse monoclonal anti-Bax antibody (clone YTH ± 2D2, raised against a synthetic peptide corresponding to amino acids (aa) 3-16) was purchased from Trevigen (Gaithersburg, MD, USA). Antibodies against p16
INK4a
(clone G175 ± 405, raised against recombinant, bacterially produced GST-p16 INK4a ), p21 CIP/WAF-1 (clone 6B6, raised against a fusion protein between GST and full-length human p21), p53 (clone DO-1, reactive against aa 1-45 of human p53), and cdk-4 (clone DCS-35, raised against human fulllength cdk-4), were all murine monoclonal antibodies and were purchased from BD-Pharmingen (Heidelberg, Germany). All antibodies (except anti-Bax which was used at 1 : 5000) were diluted 1 : 1000 (®nal concentration 0.5 mg/ml) in PBS supplemented with 0.05% Tween-20 (PBS-T) containing 3% non-fat dry milk and 0.1% NaN 3 . Secondary goatanti-mouse IgG antiserum coupled to horseradish peroxidase (HRP) was from Promega Corporation (Madison, WI, USA) and was used at a dilution of 1 : 5000 in PBS-T. JC-1 (5',5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolyl-carbocyanine iodide) was from Molecular Probes (Leiden, The Netherlands).
Immunoblotting
After trypsinization, cells were collected by centrifugation at 3006g, 48C for 5 min, washed twice with ice-cold PBS and lysed in appropriate amounts of lysis buer (10 mM Tris/ HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5 mM EDTA) supplemented with protease inhibitors (1 mM pepstatin, 1 mM leupeptin and 0.1 mM phenylmethylsulfonyl¯uoride for 30 min on ice. Samples were centrifuged at 10 0006g, 48C for 15 min and the concentration of total cellular protein was determined from the supernatants using the bicinchoninic acid assay from Pierce (Rockford, IL, USA). Thereafter, samples were mixed with sample buer (125 mM TrisHCl, 288 mM b-mercaptoethanol, 20% glycerol, 2% SDS, 10 mg/ml Bromophenol blue), boiled for 5 min, and equal amounts of protein (20 mg) were separated by SDS ± PAGE using 16 or 10% gels, respectively. Immunoblotting was performed as described (Prokop et al., 2000) . Brie¯y, nitrocellulose membranes (Schleicher & Schuell; Dassel, Germany) were rinsed in transfer buer (10 mM 3-(cyclohexylamino) propane-1-sulphonic acid, pH 11, 10% methanol) for 5 min, and blotting was performed at 1 mA/cm 2 for 1 h in a transblot semi-dry blot cell (BioRad; MuÈ nchen, Germany). Thereafter, membranes were blocked for 1 h in blocking buer (PBS-T, 3% non-fat dry milk) and incubated with primary antibodies for 1 h. After three washes with PBS-T, membranes were incubated with secondary antibody for 1 h. Finally, the membranes were washed three times in PBST and protein bands were visualized using the enhanced chemiluminescence (ECL) system and exposed to Hyper®lm (both Amersham-Buchler; Braunschweig, Germany). For control of equal protein loading, membranes were stripped in 62.5 mM Tris-HCl pH 6.8 supplemented with 100 mM bmercaptoethanol and 2% SDS at 558C for 5 min, washed three times with PBS-T and reprobed with an antibody against cdk-4.
Measurement of apoptotic cell death by flow cytometry
Apoptosis was determined on the single cell level by measuring the DNA content of individual cells by¯ow cytometry as described (Friedrich et al., 2001) . Brie¯y, cells were seeded at a density of 5610 5 cells in 75 cm 2¯a sks, cultured over night and infected with Ad-p14 ARF or Ad-lacZ under serum free conditions. After 24 to 96 h, cells were trypsinized and collected by centrifugation at 3006g for 5 min, washed once with PBS at 48C and ®xed in PBS/2% (v/v) formaldehyde for 30 min on ice. Thereafter, cells were incubated in 70% ethanol/PBS (v/v) for 20 min on ice, pelleted and resuspended in PBS containing 40 mg/ml DNasefree RNase A (Roche Molecular Biochemicals, Mannheim, Germany). After incubation for 30 min at 378C, cells were pelleted again and resuspended in PBS containing 50 mg/ml propidum iodide (Sigma, Deisenhofen, Germany). Cellular DNA content was measured with a logarithmic ampli®cation in the FL-3 channel of a FACScan¯ow cytometer (Becton Dickinson; Heidelberg, Germany) equipped with the CELLQuest software. Data are given in per cent hypoploidy (i.e. the percentage of cells with a sub-G1 DNA content), which re¯ects the percentage of apoptotic cells with fragmented genomic DNA.
Measurement of the mitochondrial permeability transition
Cells were harvested by trypsinization and washed once in PBS 24 ± 96 h post infection with recombinant adenoviruses or mock treatment. Mitochondrial permeability transition was determined by staining the cells with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanin iodide (JC-1; Molecular Probes, Leiden, The Netherlands) as described . Brie¯y, equal numbers of cells (2610 5 ) were incubated with JC-1 at 2.5 mg/ml in 500 ml DMEM without phenol red for 30 min at 378C with moderate shaking. Cells were then centrifuged at 3006g, 48C for 5 min, washed twice with ice-cold PBS and ®nally resuspended in 200 ml PBS. Mitochondrial permeability transition was subsequently quanti®ed by¯ow cytometric determination of cells with decreased¯uorescence, i.e. mitochondria displaying a lower membrane potential (DCm). Data are given in per cent cells with low DCm.
Measurement of caspase activation on the single cell level
After infection of the cells with recombinant p14 ARF adenoviruses or mock treatment, cells were cultured for 24 ± 96 h. Thereafter, cells were harvested by trypsinization and washed twice in PBS. Caspase activation was determined by incubation of cells with a¯uoresceinisothiocyanate (FITC)-labeled conjugate of the cell permeable pan-caspase inhibitor VAD ± FMK (valyl-alanyl-aspartyl-(O-methyl)-uoromethylketone) purchased from Promega Corporation (Madison, WI, USA). Equal numbers of cells (5610 5 ) were resuspended in 500 ml PBS containing FITC-VAD ± FMK at a ®nal concentration of 10 mM followed by incubation for 20 min at 378C with moderate shaking. Thereafter, cells were centrifuged at 3006g at room temperature for 5 min, washed twice with PBS and ®nally resuspended in 200 ml PBS. Caspase activation was subsequently quanti®ed by¯ow cytometric detection of cells with increased¯uorescence, i.e. through binding of FITC-labeled VAD ± FMK to activated caspases in situ. Data are given in per cent of¯uorescent cells.
